Table 4.
Capacity of MAGE-A analogs of MAGE-A2 111–125 and MAGE-12 127–141 to bind to HLA DP4 molecules
| Peptide | Sequence | IC50 (DP401) | IC50 (DP402) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 6 | 9 | Pred. | Obs. | Pred. | Obs. | ||||||||||||
| MAGE-A3 111-125 a | R | K | V | A | E | L | V | H | F | L | L | L | K | Y | R | 562 | 100 (±0) | 100 | 35 (±2) |
| MAGE-A12 111-125 a | R | K | M | A | E | L | V | H | F | L | L | L | K | Y | R | 562 | 32 (±14) | 100 | 18 (±2) |
| MAGE-A11 130-144 b | K | G | L | I | T | K | A | E | M | L | G | S | V | I | K | 1,071 | 260 (±0) | 100 | 184 (±21) |
| MAGE-A1 120-134 b | R | E | P | V | T | K | A | E | M | L | E | S | V | I | K | 3,981 | 3,800 (±424) | 302 | 424 (±35) |
| MAGE-A2 130-144 b | R | E | P | V | T | K | A | E | M | L | E | S | V | I | R | 3,981 | 2,850 (±778) | 302 | 310 (±14) |
| MAGE-A3 127-141 b | R | E | P | V | T | K | A | E | M | L | G | S | V | I | G | 3,981 | 26,500 (±2121) | 302 | 4,250 (±354) |
| MAGE-A4 128-142 b | K | E | L | V | T | K | A | E | M | L | E | R | V | I | K | 21,877 | 2,400 (±566) | 2,398 | 414 (±49) |
| MAGE-A9 126-140 b | K | E | P | V | T | K | A | E | M | L | E | S | V | I | K | 3,981 | 2,900 (±707) | 302 | 639 (±35) |
| MAGE-A10 152-166 b | K | E | P | I | T | K | A | E | I | L | E | S | V | I | K | 1,905 | 1,500 (±0) | 602 | 570 (±35) |
aThe MAGE-A analogs of MAGE-A2 111–125 and bMAGE-12 127–141 were submitted to HLA-DP4 competitive ELISA under the same conditions as described in Table 1. Predicted (Pred.) and observed (Obs.) IC50 are expressed in nM. Experimental values are the means of two to three experiments. The P1, P4, P6 and P9 positions are indicated in bold